Articles

Iridex has been granted a summary judgement, by the US District Court for the Eastern District of Missouri, on its against Synergetics.

Lux Biosciences has begun treating patients in a pivotal clinical trial programme of LX211.

Preliminary results from a Phase I trial of TargeGen's TG100801 eye drop for macular degeneration, has found it to be well tolerated in humans.

Nitric oxide-donating derivatives of latanoprost for the treatment of glaucoma have been shown to successfully lower intraocular pressure (IOP) in preclinical studies.

Tacrolimus is relatively safe and effective in reducing rejection and prolonging graft survival in subjects with high-risk keratoplasty.

Staar Surgical has revealed that its Visian toric implantable collamer lens (TICL) is unlikely to receive FDA approval in 2007.

SR Pharma has launched a Phase I clinical trial of RTP-801i.

A Phase I clinical study of Athenagen's topical eye drop therapy for wet age-related macular degeneration (AMD), ATG3, has found it to be safe and well tolerated.

Results of a Phase III trial of the once-daily formulation of Xibrom (ISTA Pharmaceuticals) has found it to be both safe and efficacious.

The 1st of March was declared "ORBIS Day" in New York City, USA, by Mayor Michael R. Bloomberg.

Eyemaginations has been selected by Carl Zeiss Meditec to release two new patient education animations.

Microincision cataract surgery (MICS) and phacoemulsification result in similar visual outcomes and early endothelial cell loss.

Fear of going blind may be more likely to motivate teenagers to stop smoking than the fear of heart or lung disease.

For most patients with choroidal neovascularization (CNV) resulting from age-related macular degeneration (AMD), triple therapy offers significant and sustained visual improvement after just one cycle of treatment.

Senior doctors have accused the independent sector treatment centre (ISTC) scheme for NHS cataract services of being an expensive over-reaction to the need to increase the rate of cataract surgery in the UK.

Glaucoma medication timolol exerts a direct antioxidant effect, protecting human endothelial cells from oxidative stress.

The annual cumulative cell loss in eyes implanted with toric iris-fixated phakic intraocular lenses (IOLs) is two to three times greater than in normal eyes without surgery.

IntraLase has entered into an agreement with Escalon Medical to settle all outstanding disputes and litigation between the parties.

GDx variable cornea compensation with scanning laser polarimetry (SLP-VCC), Heidelberg retina tomography (HRT) confocal scanning laser ophthalmoscopy (CSLO) and stereoscopic optic nerve head (ONH) photographs may all be useful in assisting clinicians to diagnose glaucoma.

Trabeculectomy is in danger of becoming a technique performed only by sub-specialists with glaucoma fellowship training unless it becomes a mandatory feature in training programmes.

Phaco-trabeculotomy in addition to deep sclerectomy can offer significant reductions in intraocular pressure (IOP).

Systemic immunosuppression following corneal transplantation should be administered only under strict medical surveillance.

Manual small incision cataract surgery (MSCIS) with trypan blue staining of the anterior capsule is a safe and effective method of cataract extraction for patients with phacolytic glaucoma.

The ICARE anterior chamber phakic intraocular lens (IOL) with angle-supported haptics was designed five years ago by Corneal Laboratories (France) and attained the CE mark for demonstrating good efficacy and stability of refractive outcomes for the correction of high myopia. However, the safety profile of the lens was compromised by a number of anatomical limitations: a high vaulting that placed the optic too close to the endothelium and, because of the overall design of the lens, accurate sizing was difficult. In our clinic, in a series of 44 cases of conventional ICARE implantations, there were three reports of ovalisation and two of endothelial cell density decrease, which necessitated the removal of the lens.

Retinal specialists have a new therapy in their armoury: on January 24th 2007, the European Commission approved ranibizumab (Lucentis, Novartis) for the treatment of patients with wet age-related macular degeneration (AMD).

The FDA has granted orphan drug designation to two of Lux Bioscience's investigational therapies.

Carl Zeiss Meditec has received FDA clearance to market the laser keratome applications of it's Visumax femtosecond laser system.

Why is it that education & training are sometimes regarded as a chore and an unnecessary obligation?

Removal of soft cataracts with Aqualase (Alcon), theoretically carries less risk to the posterior capsule than phacoemulsification.

Lumenis has appointed Dov Ofer as its new designated Chief Executive Officer.